Teva Pharmaceutical Industries Investor Presentation — December 2017

Document content

Teva Announces Restructuring Plan and

Additional Measures to Improve its Business and Financial Performance

December 14, 2017 Cautionary Note Regarding Forward -Looking Statements

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both

known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward -looking statements. Important factors that could cause or contribute to such differences include

risks relating to:

• uncertainties relating to our ability to effectively execute a restructuring plan, including : the effects of such restructuring plan, including facilities and workforce reductions, on our business, operations, revenues and profitability ; potential disruptions to our

business as a result of the restructuring and management attention to the restructuring ; uncertainty regarding the timing and amount of exit and disposal costs and severance, and the potential amount and timing of future cost savings, associated with the

restructuring and the related workforce reduction; our ability to manage the costs and liabilities associated with a restructuring plan, including exit and disposal costs and severance ; the potential loss of tax benefits in Israel as a result of our restructuring plan;

and potential labor unrest as a result of our planned workforce reductions ;

• uncertainties relating to the potential benefits and success of our new organizational structure and recent senior management changes ;

• our generics medicines business, including : that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”); our ability

to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics ; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for

generic versions of significant products ; price erosion relating to our generic products, both from competing products and as a result of increased governmental pricing pressures ; and our ability to take advantage of high-value biosimilar opportunities ;

• our specialty medicines business, including : competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally -administered alternatives ; our ability